Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base.
Saved in:
| Title: | Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base. |
|---|---|
| Authors: | Aboshi M; VLP Therapeutics Japan, Inc., 1-2-9 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Kawakami D; VLP Therapeutics Japan, Inc., 1-2-9 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Kono K; VLP Therapeutics Japan, Inc., 1-2-9 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Nishiyama A; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan., Nogimori T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan., Sunada Y; VLP Therapeutics Japan, Inc., 1-2-9 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Matsuda K; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Sekida T; VLP Therapeutics Japan, Inc., 1-2-9 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Suga S; National Hospital Organization, Mie National Hospital, Tsu, Mie 514-0125, Japan., Smith JF; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Sato N; VLP Therapeutics Japan, Inc., 1-2-9 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Yamamoto T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan.; Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, The University of Osaka, Osaka 565-0871, Japan.; Department of Virology and Immunology, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan., Akahata W; VLP Therapeutics Japan, Inc., 1-2-9 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan. |
| Source: | IScience [iScience] 2026 Jan 21; Vol. 29 (2), pp. 114766. Date of Electronic Publication: 2026 Jan 21 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
